Neurological Disorders

Fingolimod shows superior efficacy to interferon beta-1a in pediatric MS

September 21, 2018

Among pediatric patients with relapsing multiple sclerosis, fingolimod was associated with a lower annualized rate of relapse and lower incidence of new lesions identified on T2-weighted magnetic resonance imaging (MRI) compared to interferon beta-1a.

'Urgent' Need for Cannabinoid Trials in Ped Neurologic Disorders

September 21, 2018

Parents use unregulated cannabinoids to manage neurological disorders in children, including seizures, spasticity, and irritability in children with epilepsy, autism-spectrum disorder, and cerebral palsy.

Traumatic brain injury associated with higher rate of suicide

August 16, 2018

In this retrospective study, Traumatic Brain Injury (TBI) was associated with a doubling in deaths by suicide, especially within the 6 months post-TBI.

Florida Teen First Human Case of Another Mosquito-Borne Virus

June 21, 2018

"This virus is part of a group commonly known as the California serogroup of viruses," first author, John Lednicky, PhD. "These viruses are known to cause encephalitis in several species, including humans."

Immunotherapy Promising for Slowing Progression of ALS

June 04, 2018

Increased Treg suppressive function was correlated with slowing of disease progression per the Appel ALS scale for each patient.

Mild TBI Linked to Increased Dementia Risk in Veterans

May 08, 2018

The researchers observed small differences between veterans with and without TBI. Overall, 2.6 and 6.1% of those without and with TBI, respectively, developed dementia.

Educational Attainment Down With In Utero Exposure to AEDs

March 27, 2018

The researchers found that fewer children with mothers being prescribed sodium valproate during pregnancy achieved the national minimum standard in the core subject indictor (CSI), mathematics, language, and science.

Pimavanserin Evaluated in Patients With Alzheimer's Disease Psychosis

February 15, 2018

By week 12, for the overall population there was no significant advantage for pimavanserin versus placebo (treatment difference, −0.51; 95% CI, −2.23 to 1.21; P=0.561). Common adverse events in both groups included falls, urinary tract infections, and agitation.

CDC Reports Level of Significant Head Injuries Among U.S. Children

February 09, 2018

The percentage of children who have ever had a significant head injury also increased as age increased, peaking at 11.7% among 15-to-17-year-old children.

FDA Clears Smart Watch for Epilepsy Management

By February 06, 2018

Embrace uses advanced machine learning to monitor for grand mal or generalized tonic-clonic seizures, and sends an alert to summon caregivers' help.

Premature Unusual Amnesia Syndrome Linked to Substance Use

January 30, 2018

"To our knowledge this report is the first to associate fentanyl with this amnestic syndrome," the authors write.

Traumatic Brian Injury Can Occur From Head-Injury Even Without Concussion

January 23, 2018

Concussion-like deficits after impact injury, lower shear diffuse stress after blast exposure in mice

Later Seizure Disorder Risks Assessed Following Eclampsia

November 10, 2017

After a pregnancy with eclampsia, a future seizure disorder was significantly more likely (4.58/10,000 person-years) compared with a pregnancy without a hypertensive disorder of pregnancy (0.72/10,000 person-years; crude hazard ratio [HR], 6.09).

Mislabeled Muscle Spasm, Parkinson's Drugs Prompt Recall

By July 28, 2017

Accidental dosing with Cyclobenzaprine HCl may potentially lead to life-threatening serotonin syndrome when the drug is taken in combination with selective serotonin reuptake inhibitors.

Ocrevus Effective in Reducing Multiple MS Progression Markers

By June 23, 2017

The post-hoc analyses found Ocrevus to significantly decrease disease activity and disability progression in patients with RMS and PPMS, as assessed by No Evidence of Progression or Active Disease (NEPAD), a new composite endpoint in MS.

FDA Approves Brineura for Rare, Fatal Neurodegenerative Disease

By April 27, 2017

Results from the analysis showed the odds of Brineura-treated patients not having a decline were 13 times the odds of natural history cohort patients not having a decline (odds ratio 13.1, 95% CI: 1.2, 146.9).

Altered T-Cell Infusions Show Promise in Patients With Progressive MS

April 21, 2017

Over 6 months, the researchers said, none of the patients suffered serious side effects from the treatment. In addition, 3 showed symptom improvements within 2 to 8 weeks of their first T-cell infusion.

Tolerability, Adherence to Alzheimer's Drugs Assessed

By April 11, 2017

Overall, the researchers found no variation in tolerability or adherence to the 3 medications based on gender, race, education or age.

Gene Mutation for Early-Onset Parkinson's Disease ID'd

November 30, 2016

Mutated GCH1 gene tied to 23 percent increased risk of Parkinson's; symptoms five years earlier

FDA to Review Treatment for Levodopa-Induced Dyskinesia

By October 27, 2016

Adamas announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ADS-5102 (amantadine hydrochloride) extended-release capsules, to potentially treat levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD).

FDA-Approved Carnexiv Provides New Option for Certain Epilepsy Patients

By October 11, 2016

Carnexiv, an antiepileptic drug, is a short-term (≤7 days) intravenous (IV) replacement therapy for oral carbamazepine formulations in adults.

More Evidence that Zika Virus Can Cause Guillain-Barré Syndrome

October 06, 2016

Virus detected in body fluids of Colombians with Guillain-Barr syndrome

Potential ALS Treatment Under FDA Review

By August 30, 2016

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for edaravone (MCI-186; Mitsubishi Tanabe) for the treatment of amyotrophic lateral sclerosis (ALS).

Levetiracetam and Phenytoin Compared for Seizure Prophylaxis Following TBI

By July 12, 2016

A new meta-analysis found no evidence to suggest levetiracetam treatment is superior to phenytoin for early or late seizure prophylaxis in patients experiencing seizures following traumatic brain injuries (TBI)

Polygenic Scores May ID Those at Risk of Alzheimer's Disease

July 08, 2016

A genetic test may one day be able to predict the risk for Alzheimer's disease (AD) in young adults, according to a study published online July 6 in Neurology.

Study Examines QoL/Mood Outcomes of Adjunct Seizure Therapy, Lacosamide

By June 24, 2016

A 28-week open-label study of the adjunct antiepileptic drug, lacosamide, showed that it had a low risk of adverse mood effects and a low risk for overall effect on cognition.

Sabril REMS Update Ends OAF Requirement

By June 23, 2016

The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Sabril (vigabatrin; Lundbeck) tablets, meaning prescribers will no longer be required to submit an ophthalmologic assessment form (OAFs) as part of the risk evaluation and mitigation strategy (REMS).

Tablet Splitting Can Significantly Vary Doses, FDA Study Finds

By June 23, 2016

An FDA report found that certain split tablets did not meet USPs Uniformity of Dosage Units accepted criteria.

NDA for Potential ALS Treatment Submitted to FDA

By June 21, 2016

Mitsubishi Tanabe Pharma announced that a New Drug Application has been submitted to the Food and Drug Administration (FDA) for edaravone (MCI-186) for the treatment of amyotrophic lateral sclerosis (ALS).

Company Halts Clinical Program for Ganaxolone in Adult Seizures

By June 15, 2016

Marinus Pharmaceuticals announced top-line results from the Phase 3 clinical trial of ganaxolone in adults with drug-resistant focal onset seizures.